Electronic Linkage for Inflammatory Bowel Disease to Deliver Joint Access to Health Reports

Inflammatory Bowel Diseases Clinical Trial

— ELIJAH  

Official title:

Electronic Linkage for Inflammatory Bowel Disease to Deliver Joint Access to Health Reports

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02985476
• Other study ID #: 40189
• Status: Completed
• Phase: N/A
• First received: September 13, 2016
• Last updated: December 3, 2016
• Start date: May 2010
• Est. completion date: August 2011

Study information

• Verified date: December 2016
• Source: Swansea University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

This study evaluated the extent to which a shared health record facilitated better communication, increase individual responsibility for health care and reduce demand for health resources.

The study made individualised reports available to patients and General Practitioners and gave much more detail about participants chronic disease and treatments, and evaluated its effectiveness in a randomised controlled feasibility trial.

One third of patients received care as usual, two thirds of patients received the intervention.

Description:

Chronic illness is a major cause of health problems. Self-management programmes can improve care and reduce healthcare resource use, but rely on well educated patients who are able to take responsibility for their care, have effective communication with health care providers, and easy access to appropriately triaged services.

This study utilised Inflammatory Bowel Disease as an exemplar of chronic disease management.

To inform the intervention the investigators held a focus group with patients who told the investigators about their concerns relating to education, care planning and communication about their condition. The participants expressed a preference for individualised information about their care, and plans of what to do if symptoms increase.

The investigators departmental electronic patient record (GeneCIS), was extended to provide personalised, educationally enriched information to each participant about their Inflammatory Bowel Disease. The investigators customised GeneCIS to develop output reports i.e.: "My History", "My plan" and "My Update", that attach specific educational information to the detailed, structured clinical data held on the system, and shared this with participants and their General Practitioner.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 61
• Est. completion date: August 2011
• Est. primary completion date: January 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Clinical diagnosis of Inflammatory Bowel Disease, specifically Ulcerative Colitis or Crohn's Disease.

2. Aged 18 to 90 years.

3. Under the care of Consultant Gastroenterologists.

4. Patient registered with collaborating General Practitioner practice.

Exclusion Criteria:

a. Participants who are unable to comprehend the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Inflammatory Bowel Diseases
• Intestinal Diseases

Intervention

Other:
• Health reports
Participants were sent 3 sets of individualised, educationally enriched health reports about their diagnosed inflammatory bowel disease history, care plan and updates on their recent health status, results or encounters with health care services.

Locations

Country	Name	City	State
United Kingdom	Neath Port Talbot Hospital	Port Talbot	West Glamorgan

Sponsors (3)

Lead Sponsor	Collaborator
Phedra Dodds	Swansea University, The Health Foundation

Country where clinical trial is conducted

United Kingdom, 

References & Publications (7)

Osman LM, Abdalla MI, Beattie JA, Ross SJ, Russell IT, Friend JA, Legge JS, Douglas JG. Reducing hospital admission through computer supported education for asthma patients. Grampian Asthma Study of Integrated Care (GRASSIC). BMJ. 1994 Feb 26;308(6928):568-71. — View Citation

Politi P, Bodini P, Mortilla MG, Beltrami M, Fornaciari G, Formisano D, Munkholm P, Riis L, Wolters F, Hoie O, Katsanos K, O'Morain C, Shuhaibar M, Lalli P, De Falco M, Pereira S, Freitas J, Odes S, Stockbrügger RW; European Collaborative Study Group on Inflammatory Bowel Disease.. Communication of information to patients with inflammatory bowel disease: A European Collaborative Study in a multinational prospective inception cohort. J Crohns Colitis. 2008 Sep;2(3):226-32. doi: 10.1016/j.crohns.2008.01.007. — View Citation

Richardson G, Bloor K, Williams J, Russell I, Durai D, Cheung WY, Farrin A, Coulton S. Cost effectiveness of nurse delivered endoscopy: findings from randomised multi-institution nurse endoscopy trial (MINuET). BMJ. 2009 Feb 10;338:b270. doi: 10.1136/bmj.b270. — View Citation

Robinson A, Thompson DG, Wilkin D, Roberts C; Northwest Gastrointestinal Research Group.. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet. 2001 Sep 22;358(9286):976-81. — View Citation

Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Fléjou JF, Herfarth H, Hommes DW, Kupcinskas L, Lakatos PL, Mantzaris GJ, Schreiber S, Villanacci V, Warren BF; European Crohn's and Colitis Organisation (ECCO).. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis. 2008 Mar;2(1):1-23. doi: 10.1016/j.crohns.2007.11.001. — View Citation

Travis SP, Stange EF, Lémann M, Oresland T, Bemelman WA, Chowers Y, Colombel JF, D'Haens G, Ghosh S, Marteau P, Kruis W, Mortensen NJ, Penninckx F, Gassull M; European Crohn's and Colitis Organisation (ECCO).. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis. 2008 Mar;2(1):24-62. doi: 10.1016/j.crohns.2007.11.002. — View Citation

Williams JG, Cheung WY, Russell IT, Cohen DR, Longo M, Lervy B. Open access follow up for inflammatory bowel disease: pragmatic randomised trial and cost effectiveness study. BMJ. 2000 Feb 26;320(7234):544-8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety: Number of participants with adverse events as assessed by access to the primary and secondary care participant data and collated via the ELIJAH Adverse Event screening form.	The number of participants with adverse events leading to a hospital admission or otherwise, threatening the health and well being of participating patients and reported to a health professional graded according to causality and seriousness of event. Access to General Practitioner and secondary care hospital based data for the participant in paper and electronic form will provide details of relevant primary and secondary care attendances, acute admissions and outpatient appointments.	6 months	Yes
Secondary	Effectiveness: The cost of National Health Services resources used by participants in primary and secondary care.	The indirect costs of participant use of National Health services across primary and secondary care including General Practitioner visits, in-patient stays, operations, outpatient visits, investigations, Accident and Emergency attendances, open access service use and medication use will be compared. A direct cost of the intervention i.e.: the time taken by the clinician to formulate the elements of the ELIJAH intervention will be assessed. Both indirect and direct costs will be formulated via a comparrison of the PSSRU and National Schedule of reference Costs.	6 months	No
Secondary	Patient- centeredness: Participant satisfaction with disease related care provided as assessed by Inflammatory Bowel Disease Service Satisfaction Questionnaire (ISSQ, derived from the GESQ).	Participant satisfaction of the care they receive.	6 months	No
Secondary	Patient- centeredness: Participant satisfaction with disease related care provided as assessed by EQ5D.	Participant satisfaction of the care they receive.	6 months	No
Secondary	Timeliness: The average elapsed time between the onset of a new inflammatory bowel disease related issue needing a healthcare intervention for a participant, and the start of that care.	Recognition of participants noting increased symptoms , the time of reporting symptoms and response time of health professionals to respond.	6 months	No
Secondary	Equity: Whether the social status of participants affects the size of differences in the other four outcome criteria.	The number of participants designated by deprivation score (more or less deprived) using analysis of postcodes.	6 months	No